Microbial markers of irritable bowel syndrome and their applications
By screening the intestinal microbial markers Bacteroides, Dialister and Prevotella, microbial markers used to predict the efficacy of dietary therapy for low FODMAPs were solved, and the problem of difficult prediction of the treatment effect of irritable bowel syndrome in the prior art has been achieved, and more accurate Individualized treatment plans improve the effectiveness of treatment.
Patent Information
- Application Number
- CN201610066258.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2016-01-29
- Publication Date
- 2024-12-06
- Estimated Expiration
- 2036-01-29
AI Technical Summary
The prior art is difficult to effectively predict the efficacy of low FODMAPs diet for the treatment of irritable bowel syndrome, resulting in the improvement of the condition in all patients.
By screening gut microbial markers Bacteroides, Dialister and Prevotella, microbial markers are developed to predict the efficacy of dietary therapy for low FODMAPs, and detection methods and systems for the preparation of therapeutic drugs and functional foods are prepared.
It provides a microbial marker that can effectively predict the efficacy of dietary treatment for low FODMAPs in patients with irritable bowel syndrome, helps to formulate individualized treatment plans, and improves the accuracy and effectiveness of treatment.
Smart Images

Figure CN105543385B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biomarkers, and in particular, to a microbial marker for irritable bowel syndrome and its application in predicting the efficacy of a low FODMAPs diet in treating irritable bowel syndrome patients. Background Art
[0002] Irritable bowel syndrome (IBS) is a common functional gastrointestinal disease characterized by chronic recurrent abdominal pain and discomfort accompanied by changes in bowel habits. The prevalence of IBS in the general population can reach 10%-20% (J. American Gastroenterological Association, 2012, 10(7):712-721(e4)). However, the underlying pathophysiological mechanism of IBS is still not fully understood, but gastrointestinal motility abnormalities, visceral hypersensitivity, changes in brain-gut axis function, mild inflammatory reactions, and psychosocial factors may play a certain role (Camilleri M, Gastroenterology, 2001, 120(3):652-668). Studies have shown that intestinal flora disorders are also involved in the pathophysiological process of IBS. The fecal flora of IBS patients shows many changes, such as changes in abundance and diversity (Magnus S, Gut, 2013, 62(1):159-176). Therefore, intestinal microecological intervention has become a new method for treating a variety of functional gastrointestinal diseases including IBS (Proc Nutr Soc, 2010, 69(2): 187-194.).
[0003] About 20-70% of IBS patients have food intolerance (Molecular Medicine Reports, 2012, 5(6): 1382-90.), especially a class of short-chain carbohydrates called FODMAPs (monosaccharides, polysaccharides, oligosaccharides and polyols), which can cause abdominal pain, bloating symptoms and abnormal intestinal motility in IBS patients through osmotic effects and fermentation of anaerobic bacteria in the colon to produce acid and gas (Aliment Pharmacol Ther, 2010, 31(8): 874-882). Therefore, low FOMDAPs diet therapy is recommended by NICE as the first-line treatment for IBS. However, not all IBS patients can get good improvement. The lack of predictive factors for this treatment plan is a problem that needs to be solved urgently (Gastroenterol Hepatol, 2015).
[0004] The composition of intestinal microorganisms can be regulated by diet (Nutrients, 2013.5(1): p.234-52.), and diets with different FODMAPs content can change the abundance and diversity of intestinal flora to varying degrees (Gut, 2015.64(1): p.93-100.). Similarly, different intestinal microbial compositions have different degrees of utilization of different food components (Nutrients, 2013.5(1): p.234-52.). Studies have found that children with IBS who have a large number of microorganisms that mainly metabolize polysaccharides have more obvious symptom relief after a low-FODMAPs diet (Aliment Pharmacol Ther, 2015.42(4): p.418-27.). We speculate that the composition of the intestinal flora at baseline may be the main reason affecting the therapeutic effect of a low-FODMAPs diet. Therefore, screening out intestinal microorganisms that can be used as predictors of the efficacy of a low-FODMAPs diet in the treatment of irritable bowel syndrome is of great significance for the development of related therapeutic drugs. Summary of the invention
[0005] In view of the above-mentioned prior art, the first object of the present invention is to provide a microbial marker for irritable bowel syndrome.
[0006] The second object of the present invention is to provide the use of the above-mentioned microbial markers as predictors of the efficacy of FODMAPs diet in treating irritable bowel syndrome.
[0007] The third object of the present invention is to provide the use of the above-mentioned microbial markers in the preparation of drugs for treating irritable bowel syndrome and / or in the preparation of functional foods.
[0008] The fourth object of the present invention is to provide a method for detecting the above-mentioned microbial markers for non-diagnostic purposes.
[0009] The fifth object of the present invention is to provide a system for predicting the efficacy of FODMAPs dietary treatment in individual patients with irritable bowel syndrome using the above-mentioned microbial markers.
[0010] The sixth object of the present invention is to provide a drug for treating irritable bowel syndrome.
[0011] To achieve the above object, the present invention adopts the following technical solutions:
[0012] A microbial marker for irritable bowel syndrome, selected from one or more of two microorganisms, Bacteroides and Dialister, which are enriched in the irritable bowel syndrome response group to low FODMAPs diet treatment, or one microorganism, Prevotella, which is enriched in the non-responder group.
[0013] Preferably, the above-mentioned microbial markers for irritable bowel syndrome contain both the microorganism Prevotella and one or two selected from the microorganisms Bacteroides and Dialister.
[0014] The use of reagents for detecting the above-mentioned microbial markers in the preparation of a detection kit for predicting the efficacy of FODMAPs diet in treating irritable bowel syndrome is also within the protection scope of the present invention.
[0015] The above-mentioned microbial markers were determined by the inventors through comparative analysis and verification of the differences in the abundance of microorganisms in stool samples of IBS patients (including patients who respond to a low FODMAPs diet and those who do not respond), and they can be used as predictive factors for the efficacy of a FODMAPs diet in treating irritable bowel syndrome.
[0016] The present invention also provides the use of the above-mentioned microbial markers in the preparation of drugs for treating irritable bowel syndrome and / or in the preparation of functional foods.
[0017] The present invention also provides a method for detecting the above-mentioned microbial markers, the steps of which are as follows:
[0018] (1) Extract DNA samples from the subject's feces;
[0019] (2) Constructing a sequencing file for the DNA sample;
[0020] (3) performing high-throughput sequencing on the sequencing library to obtain sequencing results;
[0021] (4) determining whether the intestinal flora of the subject contains the aforementioned microbial markers based on the sequencing results;
[0022] The step (4) further comprises: detecting the relative abundance of microbial markers in the intestinal flora, and comparing the obtained relative abundance value with a predetermined cutoff value.
[0023] The present invention also provides a system for predicting the efficacy of FODMAPs dietary treatment for individual patients with irritable bowel syndrome using the above-mentioned microbial markers, comprising:
[0024] A nucleic acid sample separation unit, used to separate intestinal flora nucleic acid samples from the test subject;
[0025] A sequencing unit, used for sequencing the isolated intestinal flora nucleic acid sample to obtain a sequencing result;
[0026] A data processing unit, used to detect the relative abundance of the above microbial markers in the intestinal flora according to the sequencing results, perform ROC curve analysis on the obtained relative abundance values, and obtain the cutoff value of the above microbial markers;
[0027] A result determination unit is used to compare the cutoff values of the above microbial markers obtained by the data processing unit with the set diagnostic values. If the cutoff values of the microbial markers Bacteroides and Dialister are higher than the set diagnostic values, they are respectively scored as 1 point. If the cutoff value of the microbial marker Prevotella is lower than the set diagnostic value, it is scored as 1 point. The scores are added together. If it is higher than 2.5 points, it is determined to be positive, that is, a response to low FOMDAP diet treatment;
[0028] In the result determination unit, the set diagnostic values of the microbial markers are: the set diagnostic value of Bacteroides is 20.2%, the set diagnostic value of Dialister is 0.71%, and the set diagnostic value of Prevotella is 4.6%.
[0029] The sequencing unit adopts a high-throughput sequencing platform, preferably a HiSeq2500 PE250 sequencing platform.
[0030] The present invention also provides a detection kit for predicting the efficacy of FODMAPs diet in treating irritable bowel syndrome, wherein the kit contains reagents for detecting the above-mentioned microbial markers.
[0031] The present invention also provides a drug for treating irritable bowel syndrome, wherein the drug promotes the increase of the relative abundance of Bacteroides and / or Dialister in the microbial markers of irritable bowel syndrome;
[0032] and caused a decrease in the relative abundance of Prevotella.
[0033] The present invention also provides a method for producing or screening the above-mentioned drug, comprising the step of screening a substance that promotes the increase of the relative abundance of Bacteroides and / or Dialister in the microbial markers of irritable bowel syndrome as the drug;
[0034] And the method comprises the step of screening a substance that causes a decrease in the relative abundance of Prevotella as the drug.
[0035] Terminology Note:
[0036] Unless otherwise specified, "enrichment" in the present invention refers to bacteria that are found to have significant differences through LEfSe analysis.
[0037] "Functional food" refers to food with specific nutritional and health functions. The functional food of the present invention can regulate the amount of microorganisms Bacteroides, Dialister or Prevotella in the intestinal flora, and has an auxiliary effect on the low FOMDAP diet in the treatment of IBS.
[0038] Beneficial effects of the present invention:
[0039] (1) The present invention provides a microbial marker that can effectively predict the therapeutic effect of a low FOMDAP diet on patients with irritable bowel syndrome, and monitor the therapeutic effect of irritable bowel syndrome, and has good clinical application prospects.
[0040] (2) The present invention also provides a system for predicting and evaluating the therapeutic effect of a low FOMDAP diet using the microbial markers, and rationally and effectively applies the above microbial markers to provide patients with more accurate individualized treatment plans. BRIEF DESCRIPTION OF THE DRAWINGS
[0041] Figure 1 : Schematic diagram of the experimental analysis process of the microbial markers of the present invention.
[0042] Figure 2 : β diversity analysis based on NMDS; it can be found in the figure that the bacterial communities of responder and non-responder samples are clustered into two clusters in distribution.
[0043] Figure 3 :β diversity analysis based on PCoA; PCoA analysis found that responder samples were mainly distributed in the upper right quadrant, and non-responder samples were mainly distributed in the upper left quadrant and lower right quadrant, and MRPP analysis showed P<0.05.
[0044] Figure 4 : Marker screening / LEfSe analysis results; When LDA>4.0, at the genus level, 2 bacteria were enriched in the group that responded to the low FODMAPs diet, and 1 bacterium was enriched in the group that did not respond to the low FODMAPs diet (P<0.05).
[0045] Figure 5 : ROC curve of Example 4 prediction scoring method. DETAILED DESCRIPTION
[0046] The embodiments of the present invention will be described in detail below in conjunction with the accompanying drawings and examples, but it will be understood by those skilled in the art that the following drawings and examples are only used to illustrate the present invention, rather than to limit the scope of the present invention. In the present invention, unless otherwise specified, the scientific and technical terms used herein have the meanings commonly understood by those skilled in the art. In addition, the various laboratory operation steps used herein are all conventional steps widely used in the corresponding fields.
[0047] In the Example, we conducted an association analysis study of the entire intestinal fecal flora microorganisms on fecal samples of 34 IBS patients (16 patients who responded to a low FODMAPs diet and 18 patients who did not respond) to describe the characteristics of the fecal microbial community and functional components. In general, we obtained a total of 793 OTUs through 16S rRNA high-throughput sequencing. NMDS and PCoA found that there were statistical differences in the microbial structure and composition of the two groups; LEfSe analysis showed that when LDA>4.0, at the genus level, 2 bacteria were enriched in the responder group and 1 bacterium was enriched in the non-responder group (P<0.05). The experimental analysis process is as follows Figure 1 shown.
[0048] Example 1: Sample collection
[0049] Patients with irritable bowel syndrome were from Qilu Hospital of Shandong University. A total of 34 stool samples were collected from Chinese patients with irritable bowel syndrome, and the fresh stool sample of each individual was divided into 200 mg / portion and immediately frozen in a -80°C refrigerator.
[0050] Example 2: DNA extraction, library construction and sequencing
[0051] The microbial genomic DNA of the sample was extracted using the CTAB or SDS method, followed by PCR amplification. After library construction using the DNA PCR-Free Sample Preparation Kit, HiSeq2500PE250 was used for sequencing.
[0052] Example 3: Identification of biomarkers
[0053] 3.1 Sequencing data processing
[0054] Uparse software (Uparse v7.0.1001, http: / / drive5.com / uparse / ) was used to cluster all the effective tags of all the samples. By default, the sequences were clustered into OTUs (Operational Taxonomic Units) with a consistency of 97%. At the same time, representative sequences of OTUs were selected. According to its algorithm principle, the sequences with the highest frequency in OTUs were selected as representative sequences of OTUs. The species annotation of OTUs representative sequences was performed, and the species annotation analysis was performed using the RDP Classifier (Version 2.2, http: / / sourceforge.net / projects / rdp-classifier / ) method and the GreenGene database (http: / / greengenes.lbl.gov / cgi-bin / nph-index.cgi) (the threshold was set to 0.8-1), and the community composition of each sample was statistically analyzed at each classification level: kingdom, phylum, class, order, family, genus, and species. PyNAST software (Version 1.2) was used to perform rapid multiple sequence alignment with the "Core Set" data information in the GreenGene database to obtain the phylogenetic relationship of all OTUs representative sequences. Finally, the data of each sample was homogenized, and the sample with the least amount of data was used as the standard for homogenization to obtain the absolute abundance and relative abundance values of the sample.
[0055] 3.2 Multi-sample comparative analysis (Beta Diversity)
[0056] Qiime software (Version 1.7.0) was used to calculate Unifrac distance and construct UPGMA sample clustering tree. PCoA and NMDS plots were drawn using R software (Version 2.15.3), as follows: Figure 2 and Figure 3 As shown. PCoA analysis used WGCNA, stats and ggplot2 packages of R software, and NMDS analysis used vegan package of R software. R software was used to analyze the differences between groups of Beta diversity index, perform nonparametric tests, and perform multi-response permutation process analysis (MRPP analysis).
[0057] 3.3LEfSe analysis / screening of biomarkers
[0058] The above OTU data were analyzed using LEfSe software, with the default LDA Score screening value set to 4.0. Figure 4 As shown, two microorganisms, Bacteroides and Dialister, which had significant differences in the response group, and one microorganism, Prevotella, which was enriched in the non-responder group, were screened out.
[0059] Example 4: Establishment of a prediction scoring system
[0060] The relative abundance values of intestinal microbial markers (the determination method of abundance values is the same as 3.1 in Example 3) were subjected to receiver operating characteristic curve test (ROC curve) analysis to obtain the cutoff value (optimal cutoff value). The optimal cutoff value of Bacteroides is 20.2%, the optimal cutoff value of Dialister is 0.71%, and the optimal cutoff value of Prevotella is 4.6%. A score higher than the predetermined cuoff value of Bacteroides and Dialister, two microorganisms enriched in responders, is scored as 1 point, and a score lower than the predetermined cuoff value of Prevotella, a microorganism enriched in non-responders, is scored as 1 point. After adding all the scores, a receiver operating characteristic curve test (ROC curve) analysis was performed to select the optimal cutoff value. A score higher than the optimal cutoff value can be predicted as a response to low FODMAPs dietary treatment, and a score lower than the optimal cutoff value can be predicted as a non-response to low FOMDAPs dietary treatment. The AUC of the prediction scoring method is 0.951, the optimal cutoff value is 2.5, and the Kappa test is 0.761, which has good consistency compared with the actual treatment effect. The ROC curve of the prediction score is shown as follows. Figure 5 shown.
Claims
1. Use of a reagent for detecting microbial markers of irritable bowel syndrome in the preparation of a detection kit for predicting the efficacy of FODMAPs diet in treating irritable bowel syndrome, characterized in that: The irritable bowel syndrome microbial marker is a microorganism containing Prevotella, Bacteroides and Dialister at the same time; Bacteroides and Dialister are enriched in the group of responders to the low FOMDAPs diet treatment, and Prevotella is enriched in the group of non-responders to the low FOMDAPs diet treatment.
2. A system for predicting the efficacy of FODMAPs dietary treatment in individual patients with irritable bowel syndrome using microbial markers, characterized in that: The microbial markers are microorganisms Prevotella, Bacteroides and Dialister; The system comprises: A nucleic acid sample separation unit, used to separate intestinal flora nucleic acid samples from the test subject; A sequencing unit, used for sequencing the isolated intestinal flora nucleic acid sample to obtain a sequencing result; A data processing unit is used to detect the relative abundance of the microbial marker according to the sequencing results, perform ROC curve analysis on the obtained relative abundance value, and obtain the cutoff value of the microbial marker; A result determination unit is used to compare the cutoff value of the microbial marker obtained by the data processing unit with the set diagnostic value. If the cutoff value of the microbial markers Bacteroides and Dialister is higher than the set diagnostic value, it is scored as 1 point respectively. If the cutoff value of the microbial marker Prevotella is lower than the set diagnostic value, it is scored as 1 point. The scores are added together. If it is higher than 2.5 points, it is determined to be positive, that is, a response to low FOMDAP diet treatment; In the result determination unit, the set diagnostic values of the microbial markers are: the set diagnostic value of Bacteroides is 20.2%, the set diagnostic value of Dialister is 0.71%, and the set diagnostic value of Prevotella is 4.6%.
3. The system according to claim 2, characterized in that The sequencing unit adopts a high-throughput sequencing platform.
